Additionally, BRCA-mutant patients accounted for 41.4% of the whole sample, a much higher proportion than the presence of BRCA1/2 mutations at diagnosis of ovarian cancer patients (~25%); this fact may suggest a selection bias to receive subsequent chemotherapy (and even PARPi), probably derived from the natural evolution of both diseases (cancers harboring BRCA1/2 mutations and cancers not harboring these mutations). The gene discussed is BRCA1; the disease is ovarian carcinoma.